SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Omisirge

KPTI·Karyopharm Therapeutics Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized (FDA approved April 2023 for hematologic malignancies; December 2025 for severe aplastic anemia).
Why 3/10
Omisirge is already FDA-approved for two indications with no pending regulatory decision for this drug. KPTI is in Chapter 11 with equity being canceled, so this drug's impact on the current stock is negligible. The next catalyst is the merger closing (Q1 2027), but that is a corporate event, not a drug-specific binary.
Actionable Insight BEARISH

Omisirge is already FDA-approved with no pending regulatory binary for this drug. The key event for KPTI holders is the Chapter 11 court-supervised sale process (confirmation hearing January 11, 2027) and the proposed merger with Ayrmid closing in Q1 2027, but existing KPTI equity is expected to receive zero recovery.

Price Chart

Loading chart...

Executive Summary

Omisirge (omidubicel-onlv) is an FDA-approved cord-blood-derived stem cell therapy that reduces infection risk after stem cell transplant. It was first approved in April 2023 for hematologic malignancies and received a second approval in December 2025 for severe aplastic anemia. The drug was developed by Gamida Cell, now a subsidiary of privately held Ayrmid Ltd. Karyopharm Therapeutics (KPTI) does not currently own Omisirge, but filed for Chapter 11 bankruptcy on November 2, 2026, and entered a restructuring agreement to merge with Ayrmid. Under the plan, existing KPTI common stock will be canceled with zero recovery, making the current equity essentially worthless. The combined post-merger entity would own Omisirge alongside Karyopharm's XPOVIO, but current KPTI shareholders are not expected to participate.

How It Works

Omisirge is a stem cell therapy made from donated umbilical cord blood. The cord blood cells are processed with a form of vitamin B3 (nicotinamide) to help them grow and multiply. When infused into a patient after high-dose chemotherapy, these cells travel to the bone marrow and start making healthy new blood cells (neutrophils) faster than standard cord blood transplants, reducing the time the patient is vulnerable to serious infections.

Trial Status

Two Phase 3 trials (NCT02730299 and NCT04260698) are completed. The pivotal study (NCT02730299) enrolled 125 patients comparing omidubicel to standard cord blood transplantation and supported the initial FDA approval. An expanded access program (NCT04260698) has also completed.

The Two-Sided Case

▲ Bull Case5
Omisirge is the first FDA-approved allogeneic progenitor cell therapy for hematologic malignancies (April 2023) and the first cellular therapy for severe aplastic anemia (December 2025), addressing significant unmet needs.
The drug is a nicotinamide-modified cord blood therapy that reduces time to neutrophil recovery and infection incidence after transplant, with a differentiated mechanism.
Ayrmid (which owns Omisirge) has built a commercial platform with U.S. infrastructure and international distribution, and would bring Omisirge into the combined entity post-merger.
Institutional investors added or doubled KPTI positions in Q2 2026 (BlackRock, Goldman Sachs, Vanguard, Morgan Stanley, JPMorgan), though this data predates the Chapter 11 filing.
The combined company post-merger would have two FDA-approved products (Omisirge and XPOVIO) plus APHEXDA, creating a broader hematology portfolio.
▼ Bear Case6
KPTI filed for Chapter 11 bankruptcy on November 2, 2026; existing common stock will be canceled with zero recovery, per the 8-K filing.
Omisirge is not currently a Karyopharm asset; it is owned by Ayrmid Ltd./Gamida Cell, which is the merger partner, not the current KPTI entity.
KPTI stock closed at $0.088 on November 3, 2026, down ~21%, with a market cap around $20M, reflecting the expected equity wipeout.
Rodman & Renshaw downgraded KPTI from Buy to Neutral on November 2, 2026, the day of the Chapter 11 filing.
The Phase 3 XPORT-EC-042 trial in endometrial cancer failed its primary endpoint on July 30, 2026, adding to Karyopharm's challenges.
Omisirge faces competition from haploidentical bone marrow transplants and other alternative graft sources for stem cell transplantation.

Upcoming Catalysts

  • Chapter 11 confirmation hearing scheduled January 11, 2027.
  • Court-supervised sale process with competing bids possible; minimum bid threshold $335.4M.
  • Merger with Ayrmid expected to close in Q1 2027, but KPTI equity holders receive zero recovery.
  • FDA decision on XPOVIO sNDA for myelofibrosis expected around November 10, 2026 (a separate Karyopharm drug, not Omisirge).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Karyopharm Therapeutics Inc. 8-K KPTI ·Originating report

Sources · 12

Hover a chip for the title
1 fda.gov2 fda.gov3 fda.gov4 investors.karyopharm.com5 prnewswire.com6 fiercepharma.com7 pharmexec.com8 gamida-cell.com9 omisirge.com10 drugs.com11 sec.gov12 sec.gov